Skip to main content

TD Cowen downgrades Repare Therapeutics (RPTX) to a Hold

Tipranks - Tipranks - Tue Nov 18, 2025

Repare Therapeutics received a Hold rating and price target from TD Cowen analyst Marc Frahm today.

Meet Your ETF AI Analyst

According to TipRanks, Frahm is a 5-star analyst with an average return of 14.4% and a 51.27% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Cullinan Management, and Revolution Medicines.

In a report released on November 6, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.50 price target.

See the top stocks recommended by analysts >>

Based on Repare Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $250 thousand and a GAAP net loss of $16.74 million. In comparison, last year the company earned a revenue of $1.07 million and had a GAAP net loss of $34.77 million

Read More on RPTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).